;PMID: 2659983
;source_file_946.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..34] = [t:0..34]
;1)sentence:[e:40..213] = [t:40..213]
;2)section:[e:217..275] = [t:217..275]
;3)section:[e:279..361] = [t:279..361]
;4)sentence:[e:365..581] = [t:365..581]
;5)sentence:[e:582..720] = [t:582..720]
;6)sentence:[e:721..1066] = [t:721..1066]
;7)sentence:[e:1067..1208] = [t:1067..1208]
;8)sentence:[e:1210..1336] = [t:1210..1336]
;9)sentence:[e:1337..1540] = [t:1337..1540]
;10)sentence:[e:1541..1674] = [t:1541..1674]
;11)sentence:[e:1675..1874] = [t:1675..1874]
;12)section:[e:1878..1922] = [t:1878..1922]

;section 0 Span:0..34
;Mutat Res. 1989 Jun;212(2):275-84.
(SEC
  (FRAG (NNP:[0..5] Mutat) (NNP:[6..9] Res) (.:[9..10] .) (CD:[11..15] 1989)
        (NNP:[16..24] Jun;212-LRB-) (CD:[24..25] 2) (-RRB-:[25..26] -RRB-)
        (CD:[26..30] :275) (IN:[30..31] -) (CD:[31..33] 84) (.:[33..34] .)))

;sentence 1 Span:40..213
;Preferential activation of 6-aminochrysene and 2-aminoanthracene to mutagenic
; moieties by different forms of cytochrome P450 in hepatic 9000 X g
;supernatants  from the rat.
;[67..82]:substance:"6-aminochrysene"
;[87..104]:substance:"2-aminoanthracene"
;[150..165]:cyp450:"cytochrome P450"
;[177..183]:quantitative-value:"9000 X"
;[184..185]:quantitative-units:"g"
;[186..198]:substance:"supernatants"
(SENT
  (NP-HLN
    (NP
      (NP (JJ:[40..52] Preferential) (NN:[53..63] activation))
      (PP (IN:[64..66] of)
        (NP (NN:[67..82] 6-aminochrysene) (CC:[83..86] and)
            (NN:[87..104] 2-aminoanthracene)))
      (PP (TO:[105..107] to)
        (NP (JJ:[108..117] mutagenic) (NNS:[119..127] moieties))))
    (PP (IN:[128..130] by)
      (NP
        (NP (JJ:[131..140] different) (NNS:[141..146] forms))
        (PP (IN:[147..149] of)
          (NP (NN:[150..160] cytochrome) (NN:[161..165] P450)))))
    (PP-LOC (IN:[166..168] in)
      (NP
        (NP (JJ:[169..176] hepatic)
          (NML
             (CD:[177..181] 9000) (SYM:[182..183] X)
            (NN:[184..185] g))
          (NNS:[186..198] supernatants))
        (PP (IN:[200..204] from)
          (NP (DT:[205..208] the) (NN:[209..212] rat)))))
    (.:[212..213] .)))

;section 2 Span:217..275
;Lubet RA, McKinney CE, Cameron JW, Guengerich FP, Nims RW.
(SEC
  (FRAG (NNP:[217..222] Lubet) (NNP:[223..225] RA) (,:[225..226] ,)
        (NNP:[227..235] McKinney) (NNP:[236..238] CE) (,:[238..239] ,)
        (NNP:[240..247] Cameron) (NNP:[248..250] JW) (,:[250..251] ,)
        (NNP:[252..262] Guengerich) (NNP:[263..265] FP) (,:[265..266] ,)
        (NNP:[267..271] Nims) (NNP:[272..275] RW.)))

;section 3 Span:279..361
;Department of Genetic Toxicology, Microbiological Associates, Bethesda, MD 
;20816.
(SEC
  (FRAG (NNP:[279..289] Department) (IN:[290..292] of) (NNP:[293..300] Genetic)
        (NNP:[301..311] Toxicology) (,:[311..312] ,)
        (NNP:[313..328] Microbiological) (NNPS:[329..339] Associates)
        (,:[339..340] ,) (NNP:[341..349] Bethesda) (,:[349..350] ,)
        (NNP:[351..353] MD) (CD:[355..360] 20816) (.:[360..361] .)))

;sentence 4 Span:365..581
;6-Aminochrysene and 2-aminoanthracene were activated to metabolites which
;were  mutagenic to Salmonella typhimurium TA98 by hepatocytes or hepatic 9000
;X g  supernatants (S9s) from control or xenobiotic-treated rats.
;[365..380]:substance:"6-Aminochrysene"
;[385..402]:substance:"2-aminoanthracene"
;[421..432]:substance:"metabolites"
;[512..518]:quantitative-value:"9000 X"
;[519..520]:quantitative-units:"g"
;[522..534]:substance:"supernatants"
;[536..539]:substance:"S9s"
;[557..567]:substance:"xenobiotic"
(SENT
  (S
    (NP-SBJ-3 (NN:[365..380] 6-Aminochrysene) (CC:[381..384] and)
              (NN:[385..402] 2-aminoanthracene))
    (VP (VBD:[403..407] were)
      (VP (VBN:[408..417] activated)
        (NP-3 (-NONE-:[417..417] *))
        (PP (TO:[418..420] to)
          (NP
            (NP (NNS:[421..432] metabolites))
            (SBAR
              (WHNP-2 (WDT:[433..438] which))
              (S
                (NP-SBJ-2 (-NONE-:[438..438] *T*))
                (VP (VBD:[439..443] were)
                  (ADJP-PRD (JJ:[445..454] mutagenic)
                    (PP (TO:[455..457] to)
                      (NP (NNP:[458..468] Salmonella)
                          (NNP:[469..480] typhimurium) (NN:[481..485] TA98)))))))))
        (PP (IN:[486..488] by)
          (NP
            (NP
              (NP (NNS:[489..500] hepatocytes))
              (CC:[501..503] or)
              (NP
                (NP
                  (NML (JJ:[504..511] hepatic)
                     (CD:[512..516] 9000) (SYM:[517..518] X)
                    (NN:[519..520] g))
                  (NNS:[522..534] supernatants))
                (NP (-LRB-:[535..536] -LRB-) (NNS:[536..539] S9s)
                    (-RRB-:[539..540] -RRB-))))
            (PP (IN:[541..545] from)
              (NP
                (NP (NN:[546..553] control)
                  (NML-1 (-NONE-:[553..553] *P*)))
                (CC:[554..556] or)
                (NP
                  (ADJP (NN:[557..567] xenobiotic) (HYPH:[567..568] -)
                        (VBN:[568..575] treated))
                  (NML-1 (NNS:[576..580] rats)))))))))
    (.:[580..581] .)))

;sentence 5 Span:582..720
;Hepatocytes from  Aroclor-1254-treated rats were more efficient than
;hepatocytes from untreated  rats at activating these aromatic amines.
;[600..612]:substance:"Aroclor-1254"
;[704..719]:substance:"aromatic amines"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[582..593] Hepatocytes))
      (PP (IN:[594..598] from)
        (NP
          (ADJP (NN:[600..612] Aroclor-1254) (HYPH:[612..613] -)
                (VBN:[613..620] treated))
          (NNS:[621..625] rats))))
    (VP (VBD:[626..630] were)
      (ADJP-PRD
        (ADJP (RBR:[631..635] more) (JJ:[636..645] efficient))
        (PP (IN:[646..650] than)
          (NP
            (NP (NNS:[651..662] hepatocytes))
            (PP (IN:[663..667] from)
              (NP (JJ:[668..677] untreated) (NNS:[679..683] rats))))))
      (PP (IN:[684..686] at)
        (S-NOM
          (NP-SBJ (-NONE-:[686..686] *))
          (VP (VBG:[687..697] activating)
            (NP (DT:[698..703] these)
              (NP (JJ:[704..712] aromatic) (NNS:[713..719] amines)))))))
    (.:[719..720] .)))

;sentence 6 Span:721..1066
;When plate-incorporation and  liquid-incubation bacterial mutagenesis assays
;were performed in the presence of  limiting amounts of rat hepatic S9,
;2-aminoanthracene was activated to a greater  extent in both cases, as judged
;by his+ revertant formation, by  3-methylcholanthrene-induced hepatic S9 than
;by phenobarbital-induced or control  S9s.
;[865..867]:substance:"S9"
;[869..886]:substance:"2-aminoanthracene"
;[980..1000]:substance:"3-methylcholanthrene"
;[1017..1019]:substance:"S9"
;[1028..1041]:substance:"phenobarbital"
;[1062..1065]:substance:"S9s"
(SENT
  (S
    (SBAR-ADV (WRB:[721..725] When)
      (S
        (NP-SBJ-4
          (NP
            (NML (NN:[726..731] plate) (HYPH:[731..732] -)
                 (NN:[732..745] incorporation))
            (NML-3 (-NONE-:[745..745] *P*)))
          (CC:[746..749] and)
          (NP
            (NML (NN:[751..757] liquid) (HYPH:[757..758] -)
                 (NN:[758..768] incubation))
            (NML-3 (JJ:[769..778] bacterial) (NN:[779..790] mutagenesis)
                   (NNS:[791..797] assays))))
        (VP (VBD:[798..802] were)
          (VP (VBN:[803..812] performed)
            (NP-4 (-NONE-:[812..812] *))
            (PP (IN:[813..815] in)
              (NP
                (NP (DT:[816..819] the) (NN:[820..828] presence))
                (PP (IN:[829..831] of)
                  (NP
                    (NP (VBG:[833..841] limiting) (NNS:[842..849] amounts))
                    (PP (IN:[850..852] of)
                      (NP (NN:[853..856] rat) (JJ:[857..864] hepatic)
                          (NN:[865..867] S9)))))))))))
    (,:[867..868] ,)
    (NP-SBJ-2 (NN:[869..886] 2-aminoanthracene))
    (VP (VBD:[887..890] was)
      (VP (VBN:[891..900] activated)
        (NP-2 (-NONE-:[900..900] *))
        (PP (TO:[901..903] to)
          (NP
            (NP (DT:[904..905] a) (JJR:[906..913] greater)
                (NN:[915..921] extent))
            (PP-6 (-NONE-:[921..921] *ICH*))
            (PP-7 (-NONE-:[921..921] *ICH*))))
        (PP-LOC (IN:[922..924] in)
          (NP (DT:[925..929] both) (NNS:[930..935] cases)))
        (,:[935..936] ,)
        (SBAR-ADV (IN:[937..939] as)
          (S
            (NP-SBJ-5 (-NONE-:[939..939] *))
            (VP (VBN:[940..946] judged)
              (NP-5 (-NONE-:[946..946] *))
              (PP (IN:[947..949] by)
                (NP
                  (NML (NN:[950..953] his) (SYM:[953..954] +))
                  (JJ:[955..964] revertant) (NN:[965..974] formation))))))
        (,:[974..975] ,)
        (PP-6 (IN:[976..978] by)
          (NP
            (ADJP (NN:[980..1000] 3-methylcholanthrene) (HYPH:[1000..1001] -)
                  (VBN:[1001..1008] induced))
            (JJ:[1009..1016] hepatic) (NN:[1017..1019] S9)))
        (PP-7 (IN:[1020..1024] than)
          (PP (IN:[1025..1027] by)
            (NP
              (NP
                (ADJP (NN:[1028..1041] phenobarbital) (HYPH:[1041..1042] -)
                      (VBN:[1042..1049] induced))
                (NML-1 (-NONE-:[1049..1049] *P*)))
              (CC:[1050..1052] or)
              (NP (NN:[1053..1060] control)
                (NML-1 (NNS:[1062..1065] S9s))))))))
    (.:[1065..1066] .)))

;sentence 7 Span:1067..1208
;In contrast, 6-aminochrysene was activated more efficiently by 
;phenobarbital-induced S9 than by 3-methylcholanthrene-induced or control
;S9s.
;[1080..1095]:substance:"6-aminochrysene"
;[1131..1144]:substance:"phenobarbital"
;[1153..1155]:substance:"S9"
;[1164..1184]:substance:"3-methylcholanthrene"
;[1204..1207]:substance:"S9s"
(SENT
  (S
    (PP (IN:[1067..1069] In)
      (NP (NN:[1070..1078] contrast)))
    (,:[1078..1079] ,)
    (NP-SBJ-2 (NN:[1080..1095] 6-aminochrysene))
    (VP (VBD:[1096..1099] was)
      (VP (VBN:[1100..1109] activated)
        (NP-2 (-NONE-:[1109..1109] *))
        (ADVP
          (ADVP (RBR:[1110..1114] more) (RB:[1115..1126] efficiently))
          (PP (IN:[1127..1129] by)
            (NP
              (ADJP (NN:[1131..1144] phenobarbital) (HYPH:[1144..1145] -)
                    (VBN:[1145..1152] induced))
              (NN:[1153..1155] S9)))
          (PP (IN:[1156..1160] than)
            (PP (IN:[1161..1163] by)
              (NP
                (NP
                  (ADJP (NN:[1164..1184] 3-methylcholanthrene)
                        (HYPH:[1184..1185] -) (VBN:[1185..1192] induced))
                  (NML-1 (-NONE-:[1192..1192] *P*)))
                (CC:[1193..1195] or)
                (NP (NN:[1196..1203] control)
                  (NML-1 (NNS:[1204..1207] S9s)))))))))
    (.:[1207..1208] .)))

;sentence 8 Span:1210..1336
;This unexpected finding was confirmed employing polyclonal antibodies
;directed  against specific forms of rat cytochrome P450.
;[1258..1279]:substance:"polyclonal antibodies"
;[1320..1335]:cyp450:"cytochrome P450"
(SENT
  (S
    (NP-SBJ-1 (DT:[1210..1214] This) (JJ:[1215..1225] unexpected)
              (NN:[1226..1233] finding))
    (VP (VBD:[1234..1237] was)
      (VP (VBN:[1238..1247] confirmed)
        (NP-1 (-NONE-:[1247..1247] *))
        (S-MNR
          (NP-SBJ (-NONE-:[1247..1247] *))
          (VP (VBG:[1248..1257] employing)
            (NP
              (NP (JJ:[1258..1268] polyclonal) (NNS:[1269..1279] antibodies))
              (VP (VBN:[1280..1288] directed)
                (PP (IN:[1290..1297] against)
                  (NP
                    (NP (JJ:[1298..1306] specific) (NNS:[1307..1312] forms))
                    (PP (IN:[1313..1315] of)
                      (NP (NN:[1316..1319] rat)
                         (NN:[1320..1330] cytochrome) (NN:[1331..1335] P450)))))))))))
    (.:[1335..1336] .)))

;sentence 9 Span:1337..1540
;Thus, when employing  Aroclor-1254-induced S9 as a source of metabolic
;activation, antibody directed  against cytochrome P450IA1 inhibited the
;activation of 2-aminoanthracene but not  of 6-aminochrysene.
;[1359..1371]:substance:"Aroclor-1254"
;[1380..1382]:substance:"S9"
;[1420..1428]:substance:"antibody"
;[1447..1465]:cyp450:"cytochrome P450IA1"
;[1494..1511]:substance:"2-aminoanthracene"
;[1524..1539]:substance:"6-aminochrysene"
(SENT
  (S
    (ADVP (RB:[1337..1341] Thus))
    (,:[1341..1342] ,)
    (SBAR-ADV
      (WHADVP-1 (WRB:[1343..1347] when))
      (S
        (NP-SBJ (-NONE-:[1347..1347] *))
        (VP (VBG:[1348..1357] employing)
          (NP
            (ADJP (NN:[1359..1371] Aroclor-1254) (HYPH:[1371..1372] -)
                  (VBN:[1372..1379] induced))
            (NN:[1380..1382] S9))
          (PP-MNR (IN:[1383..1385] as)
            (NP
              (NP (DT:[1386..1387] a) (NN:[1388..1394] source))
              (PP (IN:[1395..1397] of)
                (NP (JJ:[1398..1407] metabolic) (NN:[1408..1418] activation)))))
          (ADVP-TMP-1 (-NONE-:[1418..1418] *T*)))))
    (,:[1418..1419] ,)
    (NP-SBJ
      (NP (NN:[1420..1428] antibody))
      (VP (VBN:[1429..1437] directed)
        (NP (-NONE-:[1437..1437] *))
        (PP (IN:[1439..1446] against)
          (NP (NN:[1447..1457] cytochrome) (NN:[1458..1465] P450IA1)))))
    (VP (VBD:[1466..1475] inhibited)
      (NP
        (NP (DT:[1476..1479] the) (NN:[1480..1490] activation))
        (PP
          (PP (IN:[1491..1493] of)
            (NP (NN:[1494..1511] 2-aminoanthracene)))
          (CONJP (CC:[1512..1515] but) (RB:[1516..1519] not))
          (PP (IN:[1521..1523] of)
            (NP (NN:[1524..1539] 6-aminochrysene))))))
    (.:[1539..1540] .)))

;sentence 10 Span:1541..1674
;In contrast, antibody directed against cytochrome P450IIB1  inhibited the
;activation of 6-aminochrysene but not of 2-aminoanthracene.
;[1554..1562]:substance:"antibody"
;[1580..1599]:cyp450:"cytochrome P450IIB1"
;[1629..1644]:substance:"6-aminochrysene"
;[1656..1673]:substance:"2-aminoanthracene"
(SENT
  (S
    (PP (IN:[1541..1543] In)
      (NP (NN:[1544..1552] contrast)))
    (,:[1552..1553] ,)
    (NP-SBJ
      (NP (NN:[1554..1562] antibody))
      (VP (VBN:[1563..1571] directed)
        (NP (-NONE-:[1571..1571] *))
        (PP (IN:[1572..1579] against)
          (NP (NN:[1580..1590] cytochrome) (NN:[1591..1599] P450IIB1)))))
    (VP (VBD:[1601..1610] inhibited)
      (NP
        (NP (DT:[1611..1614] the) (NN:[1615..1625] activation))
        (PP
          (PP (IN:[1626..1628] of)
            (NP (NN:[1629..1644] 6-aminochrysene)))
          (CONJP (CC:[1645..1648] but) (RB:[1649..1652] not))
          (PP (IN:[1653..1655] of)
            (NP (NN:[1656..1673] 2-aminoanthracene))))))
    (.:[1673..1674] .)))

;sentence 11 Span:1675..1874
;These  results suggest that under conditions in which the amounts of S9 added
;are  rate-limiting, the two aromatic amines are preferentially activated by
;different  induced forms of cytochrome P-450.
;[1744..1746]:substance:"S9"
;[1781..1796]:substance:"aromatic amines"
;[1857..1873]:cyp450:"cytochrome P-450"
(SENT
  (S
    (NP-SBJ (DT:[1675..1680] These) (NNS:[1682..1689] results))
    (VP (VBP:[1690..1697] suggest)
      (SBAR (IN:[1698..1702] that)
        (S
          (PP (IN:[1703..1708] under)
            (NP
              (NP (NNS:[1709..1719] conditions))
              (SBAR
                (WHPP-2 (IN:[1720..1722] in)
                  (WHNP (WDT:[1723..1728] which)))
                (S
                  (NP-SBJ
                    (NP (DT:[1729..1732] the) (NNS:[1733..1740] amounts))
                    (PP (IN:[1741..1743] of)
                      (NP
                        (NP (NN:[1744..1746] S9))
                        (VP (VBN:[1747..1752] added)
                          (NP (-NONE-:[1752..1752] *))))))
                  (VP (VBP:[1753..1756] are)
                    (ADJP-PRD (NN:[1758..1762] rate) (HYPH:[1762..1763] -)
                              (VBG:[1763..1771] limiting))
                    (PP-2 (-NONE-:[1771..1771] *T*)))))))
          (,:[1771..1772] ,)
          (NP-SBJ-1 (DT:[1773..1776] the) (CD:[1777..1780] two)
             (JJ:[1781..1789] aromatic) (NNS:[1790..1796] amines))
          (VP (VBP:[1797..1800] are)
            (VP
              (ADVP (RB:[1801..1815] preferentially))
              (VBN:[1816..1825] activated)
              (NP-1 (-NONE-:[1825..1825] *))
              (PP (IN:[1826..1828] by)
                (NP-LGS
                  (NP (JJ:[1829..1838] different) (VBN:[1840..1847] induced)
                      (NNS:[1848..1853] forms))
                  (PP (IN:[1854..1856] of)
                    (NP (NN:[1857..1867] cytochrome) (NN:[1868..1873] P-450))))))))))
    (.:[1873..1874] .)))

;section 12 Span:1878..1922
;PMID: 2659983 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1878..1882] PMID) (::[1882..1883] :) (CD:[1884..1891] 2659983)
        (IN:[1892..1893] -LSB-) (NNP:[1893..1899] PubMed) (HYPH:[1900..1901] -)
        (JJ:[1902..1909] indexed) (IN:[1910..1913] for)
        (NNP:[1914..1922] MEDLINE-RSB-)))
